Nantahala Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Nantahala Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.8M	Sell	1,797,476 -724,460	-29%	-$8.05M	0.85%	30
2026 Q1	$23.5M	Buy	2,521,936 +750,000	+42%	+$6.76M	0.87%	29
2025 Q4	$15.9M	Sell	1,771,936 -200,000	-10%	-$1.89M	0.52%	46
2025 Q3	$18.8M	Buy	1,971,936 +500,000	+34%	+$5.01M	0.65%	36
2025 Q2	$13M	Hold	1,471,936	–	–	0.51%	44
2025 Q1	$11M	Sell	1,471,936 -868,397	-37%	-$6.9M	0.44%	38
2024 Q4	$19.5M	Sell	2,340,333 -583,688	-20%	-$4.98M	0.84%	25
2024 Q3	$20.3M	Buy	2,924,021 +504,586	+21%	+$3.42M	1.03%	22
2024 Q2	$11.9M	Sell	2,419,435 -33,970	-1%	-$161K	0.69%	28
2024 Q1	$14.2M	Hold	2,453,405	–	–	0.81%	29
2023 Q4	$16.1M	Buy	2,453,405 +145,189	+6%	+$679K	0.96%	19
2023 Q3	$11.1M	Buy	+2,308,216	New	+$11.5M	0.95%	22

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Nantahala Capital Management's ZVRA Position: Q2 2026 in Review

Nantahala Capital Management reduced its Zevra Therapeutics (ZVRA) stake by 29% in Q2 2026, selling an estimated $8.05M and leaving 1,797,476 shares worth $25.8M. The position accounts for 0.85% of the portfolio, ranked #30.

Nantahala Capital Management first reported a position in ZVRA in Q3 2023 and has held it in 12 quarters since. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Nantahala Capital Management held 1,797,476 shares of Zevra Therapeutics worth $25.8M as of Q2 2026.
Nantahala Capital Management sold 724,460 Zevra Therapeutics shares in Q2 2026, an estimated $8.05M.
Zevra Therapeutics made up 0.85% of Nantahala Capital Management's portfolio in Q2 2026, its #30 holding.
Nantahala Capital Management first reported a position in Zevra Therapeutics in Q3 2023 and has held it in 12 quarters since.
158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.